Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| ASSETS | June 30,2026 | December 31,2025 |
|---|---|---|
| Preferred stock | — | — |
| Common stock | 292 | 292 |
| Capital in excess of par value of stock | 46,504 | 46,387 |
| Accumulated other comprehensive loss | (1,290) | (1,524) |
| Retained earnings | 20,316 | 16,896 |
| Less cost of treasury stock | (43,504) | (43,579) |
| Total BMS Shareholders’ equity | 22,319 | 18,473 |
| Noncontrolling interest | — | 33 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's AOCI?
- Bristol-Myers Squibb (BMY) reported AOCI of -$1.29B in Q2 2026.
- How has Bristol-Myers Squibb's AOCI changed year-over-year?
- Bristol-Myers Squibb's AOCI increased by 17.0% year-over-year, from -$1.55B to -$1.29B.
- What is the long-term trend for Bristol-Myers Squibb's AOCI?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's AOCI has grown at a -3.7% compound annual growth rate (CAGR), from -$1.84B to -$1.52B.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Bristol-Myers Squibb's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude